Difflam 3mg Lozenges - Eucalyptus Flavour

Summary of Product Characteristics Updated 06-Jul-2021 | Mylan

1. Name of the medicinal product

Difflam 3 mg Lozenges, eucalyptus flavour

2. Qualitative and quantitative composition

Each lozenge contains 3 mg of benzydamine hydrochloride equivalent to 2.68 mg of benzydamine.

Excipients with known effects: each lozenge contains 3124.43 mg of isomalt (E 953).

For the full list of excipients, see section 6.1

3. Pharmaceutical form


Dark-green square-shaped lozenges, with a central cavity.

4. Clinical particulars
4.1 Therapeutic indications

Difflam is indicated in adults and children over 6 years of age for symptomatic local treatment for the relief of pain and irritation of mouth and throat.

4.2 Posology and method of administration


Adults and children over 6 years of age: one lozenge 3 times a day.

The treatment must not exceed 7 days.

Paediatric population

Children 6-11 years of age:

The medicinal product should be administered under adult supervision.

Children below 6 years of age:

Due to the type of the pharmaceutical form, the administration should be restricted to children of more than 6 years of age.

Method of administration

For oropharingeal use.

Lozenge should be dissolved slowly in the mouth.

Do not swallow. Do not chew.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in the section 6.1.

4.4 Special warnings and precautions for use

Benzydamine use is not advisable in patient with hypersensitivity to salicylic acid or other NSAIDs.

Bronchospasm may be precipitated in patients suffering from or with a previous history of bronchial asthma. Caution should be exercised in these patients.

In a minority of patients, buccal/pharyngeal ulceration may be caused by serious disease processes. Patients whose symptoms worsen or do not improve within 3 day, or who appear feverish or have other symptoms, must therefore seek the advice of their doctor or dentist as appropriate.

Difflam contains:

Isomalt: patients with rare hereditary problems of fructose intolerance should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation


There are no or limited amount of data from the use of benzydamine in pregnant women, and animal studies are insufficient with respect to reproductive toxicity (see section 5.3).

Difflam should not be used during pregnancy.


There is insufficient information on the excretion of benzydamine in human milk.

Difflam should not be used during breast-feeding.

4.7 Effects on ability to drive and use machines

Difflam has no or negligible influence on the ability to drive and use machine, when it is used at the recommended dose.

4.8 Undesirable effects

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness

The following rate values have been used: Very common (≥ 1/10), Common (≥ 1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000) and Very rare (<1/10,000), not known (cannot be estimated from the available data).

System-Organ Class


Undesirable effect

Immune system disorders

Not Known

Anaphylactic reaction, Hypersensitivity reaction

Respiratory, thoracic, and mediastinal disorders

Very rare


Gastrointestinal Disorders


Not known

Burning mouth, Dry mouth

Hypoaesthesia oral

Skin and subcutaneous tissue disorders


Very rare



Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA yellow car in the Google Play or Apple App Store.

4.9 Overdose


No overdosage with the lozenge formulation has been reported. However, very rarely in children excitation, convulsions, sweating, ataxia, tremor and vomiting have been reported after the oral administration of benzydamine dosages about 100 times higher than those of the lozenge.


In the event of acute overdosage only symptomatic treatment is possible; the stomach should be emptied by inducing vomiting or by gastric lavage, and the patient carefully observed and given supportive treatment. Adequate hydration must be maintained.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other throat preparations, ATC code: R02AX03.

Clinical efficacy and safety

Clinical studies demonstrate that benzydamine is effective in relieving suffering from localised irritation processes of the mouth and pharynx. In addition, benzydamine possesses a moderate local anaesthetic effect.

5.2 Pharmacokinetic properties


The absorption through the mucosa of the mouth and pharynx was demonstrated by the presence of measurable quantities of benzydamine in the human plasma.


About 2 hours after the 3 mg lozenge administration, benzydamine peak plasma values of 37.8 ng/ml with an AUC of 367 ng/ml*h were observed. However, these levels are not sufficient to produce pharmacological systemic effects.

When locally applied benzydamine has been shown to accumulate in inflamed tissues where it reaches effective concentrations because of its capacity to penetrate the epithelial lining.

Biotransformation and elimination

The excretion occurs mainly in the urine and mostly in the form of inactive metabolites or conjugation products.

5.3 Preclinical safety data

Development and peri-post natal toxicity was seen in reproductive toxicity studies in rats and rabbits at plasma concentration much higher (up to 40 times) than those observed after a single therapeutic oral dose. No teratogenic effects were seen in those studies. Available kinetic data do not allow to establish the clinical relevance of the reproductive toxicity studies. As the preclinical studies had shortcomings and therefore are of restricted value, they do not provide additional information relevant for the prescriber beyond that included in other sections of the SPC.

6. Pharmaceutical particulars
6.1 List of excipients

Isomalt (E 953),

Eucalyptus oil,

Citric acid, monohydrate,

Acesulfame potassium,


Quinoline yellow (E 104),

Indigotin (E132).

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

4 years

6.4 Special precautions for storage

Do not store above 30°C.

Store in original package in order to protect from moisture.

6.5 Nature and contents of container

Lozenge is wrapped in paraffin paper.

Ten lozenges are wrapped together in printed polyethylene-paper-aluminium trilaminated material.

Each pack contains 20 or 30 lozenges (two or three packets of ten lozenges each).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Mylan Products Ltd.,

Station Close, Potters Bar,

Hertfordshire, EN6 1TL, UK

8. Marketing authorisation number(s)

PL 46302/0098

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text


Company Contact Details

Building 4, Trident Place, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL


+44 (0)1707 853 000

Medical Information Direct Line

+44 (0)1707 853 000

Customer Care direct line

+44 (0)1707 853 000 select option 2

Stock Availability

+44 (0)1707 853 000 select option 2




+44 (0)1707 261 803

Medical Information e-mail
Medical Information Fax

+44 (0)1707 261 803